Johnson & Johnson Trading Volume Drops 26% to $1.229 Billion, Ranks 49th in Daily Volume

On April 16, 2025, Johnson & Johnson (JNJ) saw a trading volume of $1.229 billion, marking a 26.23% decrease from the previous day. The company's stock price rose by 0.19%, placing it at the 49th position in terms of trading volume for the day.

Johnson & Johnson is actively recruiting for a Senior Manager, Global Labeling Product Leader position within its Innovative Medicine R&D division. This role is a hybrid position and can be located in various areas.

Joaquin Duato, the CEO of Johnson & Johnson, has expressed concerns about the potential disruption of U.S. drug supply chains due to tariffs on pharmaceuticals. He has called for a shift towards more favorable tax policies to mitigate these risks.

Johnson & Johnson has estimated that it will face $400 million in tariff-related costs. This estimate includes the impact of tariffs on aluminum and steel, as well as tariffs against key U.S. trading partners Canada and Mexico.

Johnson & Johnson's first-quarter sales increased by 2.4% worldwide, driven by the success of its medicines, including Tremfya and Carvykti. This performance has helped the company exceed analyst estimates for the quarter.

Johnson & Johnson, along with other defendants in asbestos litigation, has filed a lawsuit against 10 asbestos claims trusts in Delaware's Court of Chancery. The lawsuit aims to prevent the trusts from purging records related to asbestos claims.